

Curriculum Vitae Cosmo Pharmaceuticals S.p.A.

Board of Directors

Rolf Stahel – Chairman, Non-executive Director

Swiss (born 1944), has been Chairman of the Board of Directors of Cosmo Pharmaceuticals S.p.A. since 2006. From 2005 to 2007 he was the Deputy Chairman of the Board of Cosmo Holding S.p.A.

Rolf Stahel has a degree in business studies from KSL Lucerne, Switzerland, and he attended the advanced management programme at Harvard Business School.

From March 1994 to March 2003, he was chief executive officer of Shire Pharmaceuticals Group plc (now Shire plc). He was also a main board director and chairman of the executive committee of Shire Pharmaceuticals. From 1967 to 1994, he worked for Wellcome plc in Switzerland, Italy, Thailand, Singapore and the United Kingdom. From 1990 to 1994, he was Wellcome's director of group marketing, based in London and Beckenham, with responsibility for group strategy, R&D portfolio evaluation, marketing of existing and new products and business development. In this position, he reported directly to the chief executive officer of Wellcome plc. From 1979 to 1990, he was a regional director of Wellcome plc, based in Singapore, with responsibility for 18 Pacific Rim countries.

Chesyl Pharma Ltd., the advisory company controlled by Rolf Stahel, had business development contracts with the Company respectively Cosmo Holding S.p.A. The agreement with Chesyl Pharma Ltd. was terminated prior to the IPO.

Rolf Stahel is a member of the advisory board of the Business School of Imperial College London. In 2009 he received the lifetime achievement award from the UK Bioindustry Association.

Mauro S. Ajani - Executive Director CEO

Italian (born 1955), resident in Milan, Italy, founder and, through his holdings in Cassiopea S.A., main shareholder of Cosmo Holding S.p.A. and Cosmo Bioscience S.p.A. as well as indirectly of Cosmo Pharmaceuticals S.p.A.

Sole Director of Cosmo S.p.A. from 1998 to February 2001.

From 1994 to 1996, he was the general manager of the Russian company Italcen and took part in a joint venture of Italian and Russian entrepreneurs for the creation of a pharmaceutical product distribution company. He was a consultant of Pharmhispania from 1991 to 1993, an Italian-Spanish joint venture for the import/export and distribution of pharmaceutical products between Spain and Italy. In the period from 1983 to 1993, he was the marketing manager of Pharmajani S.r.l., a company engaged in the commercial distribution and logistics of pharmaceutical products. From 1980 to 1983, he was Nielsen's area manager for over-the-counter products of the Serono OTC company while in the period from 1978 to 1980 he worked as a salesman for the Lepetit company and for the Gazzoni company in the OTC sector.

Mauro S. Ajani is chairman and member of the board of Cosmo Bioscience S.p.A., Lainate, Milan, a company which, through its Cosmo Bioscience Inc., La Jolla, USA, subsidiary is dedicated to the development of cancer vaccines for melanoma.

In 2008, Cosmo Bioscience Inc., which is controlled by Cosmo Bioscience S.p.A., whose major shareholder is Mauro S. Ajani and his family, provided analytical services in the determination of mechanism of action of LMW Heparin for approximately USD 300 thousand.

Chris Tanner - Executive Director CFO

Swiss (born 1951), has been a Board Member of Cosmo Pharmaceuticals S.p.A. since 2006 and from 2005 to 2007 of Cosmo Holding S.p.A. Since 2006 he has been Chief Financial Officer of Cosmo Pharmaceuticals S.p.A.

Dr Tanner has a diploma as an economist and a PhD in economics from the University of St.Gallen. He joined UBS in 1977 and following a management trainee programme worked in various foreign assignments. In 1985, he became a member of the global credit committee and from 1987 to 1992 was the head of corporate banking in Asia, Australia and Africa as well as Southern Europe. In 1992 he became head of corporate finance and capital markets at UBS in Zurich. In 1998, one year after UBS's merger with SBC, he left to become a partner of Dr Ernst Müller-Möhl, co-founded the "20 Minuten" group of newspapers and founded A&A Active Investor, a listed investment company. Since 2002 he has been a corporate finance adviser and participated in numerous fund raisings amongst other for the private placement of Cosmo Holding S.p.A. He is on the advisory board of Millenium Associates, a financial adviser to the financial services industry as se-nior adviser.

He is a Beirat respectively board member of Joimax GmbH, Cosmo Bioscience, Inc. and Private Equity Holding AG which is listed on the SIX Swiss Exchange.

None of the companies that Dr Tanner is a major shareholder of has any business activities with the Company.

Friedrich von Bohlen und Halbach - Non-executive Director

German (born 1962), has been a Board Member of Cosmo Pharmaceuticals S.p.A. since 2006 and was a Member of the Board of Cosmo Holding S.p.A. from 2005 to 2007. Dr von Bohlen und Halbach has a diploma in biochemistry from the University of Zurich and a PhD in neurobiology from the Swiss Federal Institute of Technology (ETH) in Zurich. In 2008, he was appointed professor for information sciences at the University of Applied Sciences (FH) in Heidelberg, Germany.

He is founding member and shareholder of dievini Hopp BioTech Holding GmbH & Co. KG which manages the life sciences investments of the Hopp family. He has 15 years of entrepreneurial experience and was awarded numerous prizes, amongst others the McKinsey Start Up-Prize in Germany in 1998 and the German Entrepreneur of the Year Prize in 1999 by Manager Magazin, Ernst & Young and SAP.

Dr von Bohlen und Halbach is managing partner of dievini Hopp BioTech Holding GmbH & Co. KG. He is a member of the following boards: chairman of the board (Beirat) of Apogenix GmbH, Heidelberg, member of the board of Cosmo Bioscience S.p.A., Lainate, Milan, member of the board of Curacyte AG, Munich, chairman of the Board (Beirat) of CureVac GmbH, Tübingen, member of the board (Beirat) of Cytonet GmbH & Co. KG, Weinheim, member of the board of Heidelberg Pharma AG, Heidelberg, chairman of the board of Life Biosystems AG, Basel, chairman of the board of Sygnis Pharma AG, Heidelberg, and member of the board of Willex AG, Munich.

None of the unrelated companies that Dr von Bohlen und Halbach is a major shareholder of or is on the board of had any business activities with the Company.

Gianluigi Bertolli - Non-executive Director

Italian (born 1951), Dr Bertolli has been a Board Member of Cosmo Pharmaceuticals S.p.A. since 2006 and was a Board Member of Cosmo Holding S.p.A. from 2005 to 2007.

Dr Bertolli has a diploma as business and tax consultant, a diploma as chartered accountant and a PhD from the Bocconi University in Milan. He is the general secretary of Italian National Association of Chartered Accountants and president of statutory auditors of a number of major Italian and international companies.

He is the owner and head of Studio Bertolli, a firm that specializes in M&A, accounting and tax advice.

Dr Bertolli, and respectively companies that he owns, carry out a series of tax and accounting services for the Company.

Alessandro Della Chà - Non-executive Director

Italian (born 1963), has been a Board Member of Cosmo Pharmaceuticals S.p.A. since 2006.

Alessandro Della Chà has a degree in law from the University of Milan, Italy, and an LL.M. from the University of Leicester, United Kingdom, in European Union Commercial Law. He is a lecturer in conferences and seminars held by universities and institutions on commercial and company law issues.

He is also senior partner at Studio Legale Edoardo Ricci e Associati, Milan, where he specializes in company law, mergers and acquisitions. He joined the firm in 1988. From 1987 to 1988 he was assistant of the central director for corporate matters at Fininvest Group. From 1994 to 1998 he was director of II.PP.A.B. Milan (formerly ECA), a charitable institution owning hospitals and specialized in elderly care.

Studio Legale Edoardo Ricci e Associati provides a series of legal advisory services to the Company.

Dieter A. Enkelmann - Non-executive Director

Swiss (born 1959), has been a Board Member of the Company since 2006.

He graduated from the University of Zurich, where he obtained a degree in law. Dieter A. Enkelmann is chief financial officer and member of the executive management board of Julius Baer Holding AG, one of Switzerland's largest private banks, listed on the SIX Swiss Exchange. From 2003 to 2006 he was chief financial officer of Barry Callebaut AG, the world's leading manufacturer of high-quality cocoa, chocolate and confectionary products which is listed on the SIX Swiss Exchange. From 1997 to 2003 he was at Swiss Re as head of finance of the business unit

financial services and as head of corporate finance and investor relations, treasury. From 1985 to 1997 he held several positions at Credit Suisse, both in Zurich and London. Dieter A. Enkelmann is a board member of iNNutriGEL AG, Schlieren, Switzerland. Julius Baer bank provides no services for the Company.